Across TCGA pan-cancer cohorts, ZDHHC18 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZDHHC18 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ZDHHC18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC18 expression acts as an unfavorable survival marker.

DLBC, LIHC, and ESCA are the cancer types where ZDHHC18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
LIHC	DFS	Median	All	0.070	0.555	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZDHHC18 tumor-vs-normal RNA expression · all ZDHHC18 data types